NEW YORK, May 30, 2007 (PRIME NEWSWIRE) -- Cephalon, Inc. (Nasdaq:CEPH) of Frazer, Pennsylvania, will become a component of the NASDAQ-100 Index(r) (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE), and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq:NDXX) prior to market open on Friday, June 1, 2007. Cephalon, Inc. will replace MedImmune, Inc. (Nasdaq:MEDI).
With a market capitalization of approximately $5.3 billion, Cephalon, Inc. discovers, develops, and markets biopharmaceutical products to treat neurological disorders and cancer.
The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world.
NASDAQ is the largest electronic equity securities market in the United States. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to category-defining companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology industries. For more information about NASDAQ, visit the NASDAQ Web site at www.nasdaq.com or the NASDAQ Newsroom at www.nasdaqnews.com.
CONTACT: NASDAQ Media: Wayne Lee 301-978-4875 Issuer & Investor: Lisa Chaney 301-978-8281 Cephalon Media Relations: 610-344-0200